Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.

By
Andrea Surnit
June 17, 2026
3 min

Conexiant

Overview

Revise to specify that the study suggests no strong association with risks rather than implying some risk exists.

Background

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has become common for managing diabetes and weight loss. Understanding the implications of continuing these medications during pregnancy is crucial, as it affects both maternal and fetal health. This study provides important insights into the safety of GLP-1 RA continuation in early pregnancy, addressing concerns about potential adverse outcomes.

Data Highlights

Verify and update the data table to ensure it accurately reflects all relevant outcomes from the study.

Key Findings

No strong association between GLP-1 RA continuation and nonlive birth, fetal growth abnormalities, or major congenital malformations.
Adjusted risk ratio for nonlive birth was 1.09, indicating no significant difference in risk.
Elective termination rates were higher among patients who continued GLP-1 RA treatment.
Rates of spontaneous abortion were similar between both groups.
Findings were consistent across analyses stratified by type 2 diabetes status.

Clinical Implications

Healthcare providers should consider these findings when counseling patients about the risks of continuing GLP-1 RAs during early pregnancy. While the study suggests a lack of strong adverse outcomes, clinicians should remain cautious and continue to recommend discontinuation of these medications upon pregnancy recognition.